March 29th 2023
Investigators are assessing tirabrutinib, which received orphan drug designation from the FDA, as a treatment for patients with relapsed or refractory primary central nervous system lymphoma in the phase 2 PROSPECT study.
Bendamustine/Rituximab Appears Tolerable in Geriatric Mantle Cell LymphomaFebruary 9th 2023
Real-world findings from an observational study indicate that bendamustine plus rituximab appears to be well tolerated by elderly patients with transplant-ineligible mantle cell lymphoma and indolent non-Hodgkin lymphoma.
Real-World Quality-of-Life Outcomes of Axi-Cel Treatment in Lymphoma Subtypes Align With Trial DataDecember 14th 2022
Real-world data associate axicabtagene ciloleucel with temporarily worse quality of life in patients with diffuse large B cell lymphoma, transformed follicular lymphoma, or follicular lymphoma, which improves within 1-year post-infusion.
Durable Survival Benefit Observed Following HD-ASCT Vs Non-Myeloablative CRT for Primary CNS LymphomaDecember 13th 2022
Patients with with primary central nervous system lymphoma experienced prolonged progression-free survival and a reduction in risk of death following treatment with high-dose chemotherapy and autologous stem cell transplant compared with non-myeloablative chemoimmunotherapy.
FDA Accepts BLA for Denileukin Diftitox in Cutaneous Persistent/Recurrent T-Cell LymphomaDecember 4th 2022
The FDA’s acceptance of the biologics license application for denileukin diftitox for the treatment of patients with cutaneous persistent or recurrent T-cell lymphoma was supported by data from a pivotal phase 3 trial.
Zandelisib Demonstrates Promising Responses in Relapsed/Refractory Non-Hodgkin LymphomaNovember 21st 2022
Topline results from the phase 2 MIRAGE study indicated that patients with relapsed/refractory indolent B-cell non-Hodgkin lymphoma receiving zandelisib experienced an objective response rate of 75.4%.
Confirmatory Phase 3 Trial Needed Prior to Camidanlumab Tesirine BLA Submission for Accelerated Approval Path, FDA SaysNovember 11th 2022
For camidanlumab tesirine to be considered for an accelerated approval path in relapsed/refractory Hodgkin lymphoma, the FDA has strongly recommended conducting confirmatory phase 3 research at the time of biologic license application submission.
European Commission Grants Approval to Second-Line Axicabtagene Ciloleucel for R/R DLBCL/HGBLOctober 22nd 2022
The European Commission based its approval of axicabtagene ciloleucel as a second-line therapy for patients with relapsed/refractory diffuse large B-cell lymphoma or high-grade B-cell lymphoma on the efficacy findings of the phase 3 ZUMA-7 trial.
Tafasitamab Plus Lenalidomide Improve Outcomes Vs Systemic Therapies in Relapsed/Refractory DLBCLOctober 9th 2022
Tafasitamab plus lenalidomide prolonged overall survival compared with systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphoma, according to data from the retrospective RE-MIND2 study.
Sugemalimab Study Highlights Notable Clinical Promise in Relapsed/Refractory ENKTL, Says Ranjit Nair, MDSeptember 6th 2022
Ranjit Nair, MD, discusses the promise of sugemalimab, both as a single-agent and as part of a combination regimen, in patients with relapsed/refractory extranodal natural killer/T-cell lymphoma.
Supplemental BLA Accepted by FDA for Polatuzumab Vedotin/R-CHP Combo for Previously Untreated DLBCLAugust 17th 2022
Patients with previously untreated diffuse large B-cell lymphoma may benefit from treatment with polatuzumab vedotin-piiq plus rituximab, cyclophosphamide, doxorubicin, and prednisone, for which a supplemental biologics license application was accepted by the FDA.
Intermittent Dosing Schedule for Zandelisib Appears Safe With Low Incidence of High-Grade AEs in R/R B-Cell MalignanciesJuly 30th 2022
Patients with relapsed/refractory B-cell malignancies who received zandelisib at 60 mg via an intermittent dosing schedule experienced a low incidence of grade 3 or higher adverse effects.
Fixed-Duration Mosunetuzumab Yields Promising Safety, Remission Rates in Relapsed/Refractory Follicular LymphomaJuly 29th 2022
Patients with relapsed/refractory follicular lymphoma with 2 or more prior therapies experienced promising safety and remission rates following treatment with mosunetuzumab.
Findings Support Liso-Cel in the Second-Line for Large B-Cell Lymphoma Not Intended for HSCTJuly 28th 2022
Findings from the phase 2 TRANSCEND-PILOT-017006 supported the use of lisocabtagene maraleucel as a second-line treatment for patients with large B-cell lymphoma who were not able to or didn’t want to receive hematopoietic stem cell transplant.
Pegasparaginase-Based Chemotherapy Yields Promising Preliminary Results in Extranodal Natural Killer/T-Cell LymphomaJuly 21st 2022
Dexamethasone, Cisplatin, gemcitabine, and pegaspargase resulted in improved preliminary outcomes vs dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide for patients with newly diagnosed locally advanced stage III or IV extranodal natural killer/ T-cell lymphoma.
FDA Grants Fast Track and Rare Pediatric Disease Designation to WU-CART-007 in R/R T-Cell ALL/LBLJuly 20th 2022
WU-CART-007 was granted fast track and rare pediatric disease designation by the FDA for the treatment of patients with relapsed/refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma.
Phase 2 Alliance A059102 Trial Will Assess the Efficacy of Duvelisib/Azacitidine Plus CHOP/CHOEP for Peripheral T-Cell LymphomaJuly 1st 2022
In the phase 2 Alliance A059102 trial, patients with treatment-naïve CD30-negative peripheral T-cell lymphoma will be treated with duvelisib and azacitidine plus CHOP/CHOEP chemotherapy.